Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Apr;11(4):1555-1557.
doi: 10.4103/jfmpc.jfmpc_1975_21. Epub 2022 Mar 18.

Post immunization COVID-19 disease

Himmatrao S Bawaskar  1 , Pramodini H Bawaskar  1
Affiliations
Case Reports

Post immunization COVID-19 disease

Himmatrao S Bawaskar et al. J Family Med Prim Care. 2022 Apr.

Abstract

One hundred and two patients reported to peripheral hospital, of these 73 (77%) and 23 (95%) suffered from COVID-19 disease, were immunized as per availability of Covishield 78 (77%) and Covaxin 24 (23%), respectively. Of these, three died (3%). Inflammatory markers were raised in Covishield vs. Covaxin 26 (36%) vs. 7 (31%), 46 (63%) vs. 8 (35%), 57 (78%) vs. 14 (61%), 29 (40%) vs. (73%), C-reactive proteins and serum ferritin, and positive for COVID-19 antigen and RTPCR and COVID-19 pneumonia, respectively. Irrespective of immunization status of victim with symptoms should be investigated for possibility of severe acute respiratory syndrome COVID-beta 2 (SARS-CoV-2) virus infection. These findings confirmed the need for a Booster dose of COVID-19 vaccination.

Keywords: COVID-19; HRCT; vaccine.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Showing the HRCT score23/25 in a 69 years old male 15 days after the second dose of covaxin, died on 7th day of hospitalizations
See this image and copyright information in PMC

References

    1. India's Covid-19 emergency. Lancet. 2021;397:1683. - PMC - PubMed
    1. Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368:945–6. - PubMed
    1. Raina SK, Kumar R. Diagnostic tools for evaluating the effectiveness of COVID-19 vaccines:Challenges and solution. J Family Med Prim Care. 2021;10:2059–61. - PMC - PubMed
    1. Wise J. Covid-19:European countries suspend use of Oxford –AstraZeneca vaccine after report of blood clot. BMJ. 2021;372:n699. - PubMed
    1. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody –dependent enhancement and SARS-cov-2 vaccines and therapies. Nat Microbiol. 2020;5:1185–91. - PubMed

Publication types